|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001675,
umls-concept:C0019682,
umls-concept:C0019691,
umls-concept:C0042210,
umls-concept:C0085432,
umls-concept:C0205263,
umls-concept:C0276199,
umls-concept:C0301872,
umls-concept:C0332307,
umls-concept:C1171370,
umls-concept:C1257890,
umls-concept:C1513895
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1998-5-29
|
|
pubmed:abstractText |
A safety and immunogenicity trial was conducted in vaccinia-immune and vaccinia-naive human immunodeficiency virus (HIV)-uninfected adults who were randomized to receive 10(6) or 10(7) TCID50 of canarypox (ALVAC) vector expressing HIV-1MN gp160 or 10(5.5) TCID50 of ALVAC-rabies virus glycoprotein control at 0 and 1 or 2 months and ALVAC-gp160 or 50 microg of HIV-1SF2 recombinant (r) gp120 in microfluidized emulsion at 9 and 12 months; others received rgp120 at 0, 1, 6, and 12 months. All vaccines were well-tolerated. Neither vaccinia-immune status before vaccination nor ALVAC dose affected HIV immune responses. HIV-1MN and HIV-1SF2 neutralizing antibodies were detected more often (100%) in ALVAC-gp160/rgp120 recipients than in recipients of ALVAC-gp160 (<65%) or rgp120 (89%) alone. ALVAC-gp160/rgp120 also elicited more frequent HIV V3-specific and fusion-inhibition antibodies, antibody-dependent cellular cytotoxicity, lymphoproliferation, and cytotoxic CD8+ T cell activity than did either vaccine alone. Trials with ALVAC expressing additional HIV components and rgp120 are underway.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0022-1899
|
|
pubmed:author |
pubmed-author:BelsheRR,
pubmed-author:Clements-MannM LML,
pubmed-author:CoreyLL,
pubmed-author:DolinRR,
pubmed-author:ExclerJ LJL,
pubmed-author:FastPP,
pubmed-author:GAYJ GJG,
pubmed-author:GorseG JGJ,
pubmed-author:GrahamB SBS,
pubmed-author:HsiehR HRH,
pubmed-author:JacksonSS,
pubmed-author:KeeferM CMC,
pubmed-author:MascolaJJ,
pubmed-author:MatthewsT JTJ,
pubmed-author:McElrathM JMJ,
pubmed-author:MesteckyJJ,
pubmed-author:PaolettiEE,
pubmed-author:SchwartzDD,
pubmed-author:SilicianoRR,
pubmed-author:StableinDD,
pubmed-author:TartagliaJJ,
pubmed-author:WalkerM CMC,
pubmed-author:WeinholdKK,
pubmed-author:WrightP FPF,
pubmed-author:Zolla-PaznerSS
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
177
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
1230-46
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:9593008-AIDS Vaccines,
pubmed-meshheading:9593008-Adult,
pubmed-meshheading:9593008-Antibody Formation,
pubmed-meshheading:9593008-Antibody-Dependent Cell Cytotoxicity,
pubmed-meshheading:9593008-CD8-Positive T-Lymphocytes,
pubmed-meshheading:9593008-HIV Antibodies,
pubmed-meshheading:9593008-HIV Envelope Protein gp120,
pubmed-meshheading:9593008-HIV-1,
pubmed-meshheading:9593008-Humans,
pubmed-meshheading:9593008-Immunization, Secondary,
pubmed-meshheading:9593008-Immunization Schedule,
pubmed-meshheading:9593008-Lymphocyte Activation,
pubmed-meshheading:9593008-Lymphocytes,
pubmed-meshheading:9593008-Neutralization Tests,
pubmed-meshheading:9593008-Rabies virus,
pubmed-meshheading:9593008-Time Factors,
pubmed-meshheading:9593008-Vaccines, Synthetic,
pubmed-meshheading:9593008-Viral Vaccines
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
|
|
pubmed:affiliation |
Johns Hopkins University School of Public Health, Baltimore, Maryland, USA. mclement@jhsph.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
